Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of Oral Decitabine/Cedazuridine as Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Patients With Myeloid Neoplasms

NCT04980404 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT04980404
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04980404 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of Oral Decitabine/Cedazuridine as Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Patients With Myeloid Neoplasms
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 17, 2021
Completion date
November 30, 2026
Enrollment
22 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelomonocytic leukemia, myelodysplastic syndromes, stem cell leukemia